<unk> s drugs are well tolerated by healthy humans. These drugs are already in mainstream use to treat patients with different kinds of psychiatric disorders. Since most of the information on<unk> s and its capabilities are drawn from research experiments, the best way to determine adverse effects are drop-out rates and subjective rating. The drop-out rates were minimal or non-existent for donepezil, memantine, MPH, and modafinil. In the drug trials, participants reported the following adverse reactions to the consumption of donepezil, memantine, MPH, or modafinil: gastrointestinal complaints (nausea), headache, dizziness, nightmares, anxiety, drowsiness, nervousness, restlessness, sleep disturbances, and insomnia. The side effects normally ceased in the course of treatment. While there were no reported side effects from DBS, 18% of the patients suffered from device related complications such as infections due to lead dislodgment or breakage.
Neuroenhancement
Neuroprotection
Neural binding
Neuroregeneration
Neurostimulation
Wasting
Remyelination
Bioaccumulation